Takuji Sato

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

Keiichi Sakakibara, Naoya Saito, Takuji Sato et al. · Blood · 2011 · 118 citations

Pharmacy, Medicinal Chemistry, Pharmacology +3

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint

Shi-Ken Sha, Takuji Sato, Hidetaka Kobayashi et al. · Molecular Cancer Therapeutics · 2007 · 50 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway

Naoya Saito, Keiichi Sakakibara, Takuji Sato et al. · Molecular Cancer Therapeutics · 2014 · 27 citations

Life Sciences, Molecular Biology, Oncology +15

CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice

Keiichi Sakakibara, Takuji Sato, Donald Küfe et al. · Oncotarget · 2017 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17